Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERMIN: Permixon vs Tamsulosin in BPH
NCT01604811Phase 4Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Jun 2012
- Primary completion
- Oct 2013
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 4, randomised, double-blind trial of permixon in benign prostatic hyperplasia (BPH) (2 arms), sponsored by Pierre Fabre Laboratories. Primary endpoint: Change from baseline of Inflammation Biomarkers at Day 90. Started Jun 2012; status: completed.
02
Drugs
permixon
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on NCT01604811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01604811.